Cargando…
FL118, acting as a ‘molecular glue degrader’, binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c‐Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC), a difficult‐to‐treat cancer, is expected to become the second‐largest cause of cancer‐related deaths by 2030, while colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer deaths. Currently, there is no effect...
Autores principales: | Ling, Xiang, Wu, Wenjie, Aljahdali, Ieman A. M., Liao, Jianqun, Santha, Sreevidya, Fountzilas, Christos, Boland, Patrick M., Li, Fengzhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126027/ https://www.ncbi.nlm.nih.gov/pubmed/35604033 http://dx.doi.org/10.1002/ctm2.881 |
Ejemplares similares
-
Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer
por: Santha, Sreevidya, et al.
Publicado: (2020) -
Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
por: Li, Fengzhi, et al.
Publicado: (2019) -
Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein–Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases
por: Li, Fengzhi, et al.
Publicado: (2022) -
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma
por: Li, Fengzhi, et al.
Publicado: (2021) -
A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity
por: Ling, Xiang, et al.
Publicado: (2012)